Meet the Surgical Oncology Physicians
Home > Cancer (Oncology) > Services and Treatments > Surgical Oncology > Meet the Surgical Oncology Physicians

Services and Treatments

Meet the Surgical Oncology Physicians

Lisa S. Wiechmann, MD

Practice Specialty
Surgery, Breast Surgery, Surgical Specialties
Medical Education
Universita Degli Studi Di Firenze
Boston University Medical Center Hospital, Caritas St. Elizabeth's Medical Center
Memorial-Sloan Kettering Cancer Center
Board Certified
Academic Title
Assistant Professor, Department of Surgery
Administrative Title
Attending Surgeon, Division of Breast Surgery
Clinical Focus
Breast Surgery, Breast Cancer
Research Focus

In the clinic, Dr. Wiechmann's interests include triple negative breast cancer (ER, PR, and HER2 negative), the genetic and familial predisposition to breast cancer, and breast cancer chemoprevention.


Dr. Wiechmann is a board certified surgeon specializing in breast cancer, who has been recognized with honors by the Breast Cancer Alliance, the Susan G. Komen for the Cure foundation and the Society of Surgical Oncology. Upon earning her medical degree with honors at Universita' Degli Studi Di Firenze Facolta' Di Medicina e Chirurgia in Florence, Italy, she conducted her residency in surgery at St. Elizabeth's Medical Center in Boston. After completing her residency, she conducted research at the Lester and Sue Smith Breast Center of the Dan L. Duncan Cancer Center at Baylor College of Medicine, in Houston, Texas. At Baylor, her research focused on the preclinical development of therapies targeting the HER2 receptor; her work was recognized by Komen/AACR. Dr Wiechmann was thereafter the recipient of the Breast Cancer Alliance award that funded her clinical fellowship at Memorial Sloan-Kettering Cancer Center.
After completing her fellowship, she participated in the prestigious ASCO/AACR (American Society for Clinical Oncology/American Association for Cancer Research) course, Methods in Clinical Cancer Research, and developed a protocol that investigates the effect of transdermal tamoxifen on the growth of breast cancer cells with the ultimate goal of using it for breast cancer prevention.